SARMs Human clinical data

Ostarine (MK-2866 / Enobosarm)

MK-2866 · Enobosarm

24 hours

Half-life

10–25 mg

Typical dose

Oral, daily

Frequency

6–8 weeks (community protocols)

Cycle length

Non-steroidal SARM; mild, used in cutting/recomp. Simple model (estimated).

Key takeaways

Mild, well-studied SARM: phase 2 trials showed dose-dependent lean mass gains at just 1–3 mg daily.
Estimated 24-hour half-life supports once-daily dosing; the plotter curve is modeled from LGD-4033 data.
Suppression, lipid shifts, and liver enzymes worsen at off-label doses, so bloodwork and PCT planning matter.
Unapproved and WADA-prohibited; grey-market products are frequently mislabeled or contaminated.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Clinical trial (phase 2)	1–3 mg	Oral	Once daily	Up to 12 weeks
Physique (community)	10–25 mg	Oral	Once daily	6–8 weeks

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 24 hours
Bioavailability: 100%
Typical dose: 10–25 mg

Harm reduction

Aromatizes: No
Hepatotoxicity: mild
Injection frequency: Oral, daily

Frequently asked questions

Is ostarine legal and approved?

No approved medical use exists anywhere. It's sold as a research chemical, prohibited by WADA, and banned from dietary supplements in several countries. Grey-market products are frequently mislabeled or contain different compounds than the label claims.

How suppressive is ostarine?

Dose-dependent. Trial doses (1–3 mg) caused mild, reversible changes; community doses (10–25 mg) commonly show measurable LH, FSH, and total testosterone drops on bloodwork. A PCT plan before starting is standard harm-reduction practice, not an afterthought.

Is the plotter's ostarine curve accurate?

It's an estimate. Published human PK data are limited, so the profile is modeled by comparison to LGD-4033. Use it for relative timing (peak shape, accumulation, washout) rather than exact nanogram-per-mL values.

References

Ostarine PK (estimated) — Estimated by comparison to LGD-4033.
Dalton et al., J Cachexia Sarcopenia Muscle 2011 — phase 2 RCT — GTx-024 improved lean body mass and physical function at 1–3 mg daily over 12 weeks.
GTx-024 ADME study, Xenobiotica 2013 — Absorption, distribution, metabolism, and excretion data behind the PK estimate.

Comments

Loading comments…